Design, Formulation and Optimization of Methotrexateloaded Buccal Films for Oral Cancer
Year: 2026
Type: article
Abstract: Oral squamous cell carcinoma is commonly managed with surgery, radiotherapy, and systemic therapy. Local drug-delivery systems may offer an additional approach by maintaining drug contact with the oral mucosa. Methotrexate (MTX) is an antimetabolite anticancer drug; however, its formulation may be challenging because of its physicochemical properties. This study aimed to prepare a methotrexate–β-cyclodextrin (MTX–β-CD) inclusion complex and incorporate it into mucoadhesive buccal films, followed by formulation, evaluation, and selection of a candidate formulation. The inclusion complex was prepared by kneading at a 1:1 molar ratio. Phase-solubility analysis, Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), and X-ray diffraction (XRD) were used for characterization. Films were prepared by solvent casting using HPMC E15 and sodium carboxymethylcellulose (Na CMC), with PEG 400 as the plasticizer and mannitol as an excipient. A 2² factorial design with three centre-point formulations was used to examine the effects of polymer concentrations on mucoadhesive strength, folding endurance, and drug release. The phase-solubility study showed a linear AL-type profile (R² = 0.9997). The inclusion complex had a practical yield of 91.42 ± 1.01% and a drug content of 92.59 ± 1.04%. Across formulations F1–F7, mucoadhesive strength ranged from 0.180 ± 0.002 to 0.312 ± 0.002 N, folding endurance from 226 ± 3 to 288 ± 2 folds, swelling index from 28.9 ± 0.3% to 37.7 ± 0.3%, and drug release at 30 min from 77.9% to 96.2%. Formulation F2 (300 mg HPMC E15 and 100 mg Na CMC) was selected as the candidate formulation based on an overall balance of adhesion, flexibility, and drug release. It showed a mucoadhesive strength of 0.237 N, folding endurance of 254 ± 2 folds, and drug release of 89.8% at 30 min. The optimized film showed concentration-dependent cytotoxicity against SCC-9 oral squamous cell carcinoma cells, with a reported IC₅₀ of 74.40 µg/mL, compared with 53.70 µg/mL for 5-fluorouracil. One-month stability observations showed only minor changes in the measured parameters. These findings support further investigation of MTX–β-CD buccal films; additional validation and in-vivo studies are required before therapeutic conclusions can be drawn.
Language: English
Subfield: Pharmaceutical Science
Domain: Life Sciences
Keywords: methotrexate, buccal films, oral squamous cell carcinoma, β-cyclodextrin, inclusion complexes, mucoadhesion, HPMC E15, carboxymethyl cellulose, drug release, phase solubility, factorial design, oral drug delivery, mucoadhesive strength, folding endurance, swelling index, solvent casting, anticancer agents
Open Access status: green
OpenAlex ID: W7236177134
